Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2017

Open Access 01-03-2017 | Case Report

Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report

Authors: A. Fahrleitner-Pammer, D. Wagner, P. Krisper, K. Amrein, H. Dimai

Published in: Osteoporosis International | Issue 3/2017

Login to get access

Abstract

Low-turnover bone disease is a complication of chronic kidney disease and a long-term steroid therapy. Currently, the only bone anabolic treatment available is teriparatide (TPTD). So far, no data exist in heart transplant patients, and only one single case with histomorphometric analysis of a dialysis patient with a low-turnover bone disease has been published. The current report shows the effect of a 1-year TPTD therapy in a cardiac transplant patient with 10 vertebral and 3 peripheral fractures who had developed a chronic kidney failure while receiving triple immunosuppressive therapy. A transiliac bone biopsy following tetracycline labeling was performed prior and after 1 year of treatment, showing an increase in the bone formation and improvement of the structural indices (20-fold increase of osteoid volume/bone volume, fourfold increase of osteoid surface/bone surface and increases of wall thickness (+15%), trabecular thickness (+9%), and trabecular number (+38%)). Bone mineral density was stable, no new vertebral fractures had occurred, the therapy was well-tolerated, and the patient improved clinically.
Literature
1.
Cohen A, Sambrook P, Shane E (2004) Management of bone loss after organ transplantation. J Bone Miner Res 9:1919–1932CrossRef
2.
Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH et al (2015) Revisiting KDIGO clinical practice guideline on chronic kidney disease—mineral and bone disorder: a commentary from a Kidney Disease: improving global outcomes controversies conference. Kidney Int 87:502–528CrossRefPubMed
3.
Pelletier S1, Confavreux CB, Haesebaert J, Guebre-Egziabher F, Bacchetta J, Carlier MC et al (2015) Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int 26(8):2165–2174CrossRefPubMed
4.
Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013 May) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8(5):819–823CrossRefPubMedPubMedCentral
5.
de Oliveira RA, Barreto FC, Mendes M, dos Reis LM, Castro JH, Britto ZM et al (2015 May) Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int 87(5):1039–1045CrossRefPubMed
6.
Moysés RM, Schiavi SC (2015 Nov-Dec) Sclerostin, osteocytes, and chronic kidney disease—mineral bone disorder. Semin Dial 28(6):578–586CrossRefPubMed
7.
Miller PD (2014 Aug) Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 64(2):290–304CrossRefPubMed
8.
Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP et al (2009) Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335–1344CrossRefPubMed
9.
Malluche HH, Porter DS, Monier-Faugere MC, Mawad H, Pienkowski D (2012) Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol 23:525–532CrossRefPubMedPubMedCentral
10.
Jamal SA, Gilbert J, Gordon C, Bauer DC (2006) Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21:543–548CrossRefPubMed
11.
12.
Jamal SA1, Ljunggren O, Stehman-Breen C, Cummings SR, MR MC, Goemaere S (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829–1835CrossRefPubMed
13.
Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26:1368–1376CrossRefPubMed
14.
Cejka D, Kodras K, Bader T, Haas M (2010) Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study. Kidney Blood Press Res 33:221–226CrossRefPubMed
15.
Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18(1):59–68CrossRefPubMed
16.
Palcu P, Dion N, Ste-Marie LG, Goltzman D, Radziunas I, Miller PD et al (2015) Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. Am J Kidney Dis 65:933–936CrossRefPubMed
17.
Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The study of osteoporotic fractures research group J Bone Miner Res 1996;11(7):984–996.
18.
Krege JH, Lane NE, Harris JM, Miller PD (2014) PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int 25(9):2159–2171CrossRefPubMedPubMedCentral
19.
Delanaye P, Souberbielle JC, Lafage-Proust MH, Jean G, Cavalier E (2014) Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Nephrol Dial Transplant 29:997–1004CrossRefPubMed
20.
Cavalier E, Bergmann P, Bruyère O, Delanaye P, Durnez A, Devogelaer JP et al (2016) The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos Int 27:2181–2195CrossRefPubMed
21.
Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H et al (2008) Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 23(11):1850–1858CrossRefPubMed
22.
Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941CrossRefPubMed
23.
Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H et al (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17CrossRefPubMedPubMedCentral
24.
Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S (1988) Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3:133–144CrossRefPubMed
25.
Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L et al (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16(10):1846–1853CrossRefPubMed
26.
Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970–3977CrossRefPubMed
27.
Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2005) Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Clin Endocrinol Metab 90:3970–3977CrossRef
28.
Mitsopoulos E, Ginikopoulou E, Economidou D, Zanos S, Pateinakis P, Minasidis E (2012) Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study. Am J Nephrol 36:238–244CrossRefPubMed
Metadata
Title
Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report
Authors
A. Fahrleitner-Pammer
D. Wagner
P. Krisper
K. Amrein
H. Dimai
Publication date
01-03-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 3/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3858-2

Other articles of this Issue 3/2017

Osteoporosis International 3/2017 Go to the issue

Case Report

Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates

Original Article

Diverging results of areal and volumetric bone mineral density in Down syndrome

Original Article

Addition of a fracture risk assessment to a coordinator’s role improved treatment rates within 6 months of screening in a fragility fracture screening program

Original Article

Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States

Original Article

Association of circulating dipeptidyl-peptidase 4 levels with osteoporotic fracture in postmenopausal women

Original Article

Increased CD14+ and decreased CD14− populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients